Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11592410rdf:typepubmed:Citationlld:pubmed
pubmed-article:11592410lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:11592410lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:11592410lifeskim:mentionsumls-concept:C1513016lld:lifeskim
pubmed-article:11592410pubmed:issue8lld:pubmed
pubmed-article:11592410pubmed:dateCreated2001-10-10lld:pubmed
pubmed-article:11592410pubmed:abstractTextMatrix metalloproteinases (MMPs) are a family of zinc endopeptidases that have been implicated in various disease processes. Different classes of MMP inhibitors, including hydroxamic acids, phosphinic acids and thiols, have been previously described. Most of these mimic peptides and most likely bind in a similar way to the corresponding peptide substrates. Here we describe pyrimidine-triones as a completely new class of metalloprotease inhibitors. While the pyrimidine-trione template is used as the zinc-chelating moiety, the substituents have been optimized to yield inhibitors comparable in their inhibition efficiency of matrix metalloproteinases to hydroxamic acid derivatives such as batimastat. However, they are much more specific for a small subgroup of MMPs, namely the gelatinases (MMP-2 and MMP-9).lld:pubmed
pubmed-article:11592410pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:languageenglld:pubmed
pubmed-article:11592410pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:citationSubsetIMlld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11592410pubmed:statusMEDLINElld:pubmed
pubmed-article:11592410pubmed:monthAuglld:pubmed
pubmed-article:11592410pubmed:issn1431-6730lld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:ZimmermannGGlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:LeinertHHlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:GrafAAlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:OlivaAAlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:BrandstetterH...lld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:MenthLLlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:KrellH WHWlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:GramaPPlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:D'AlòSSlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:GeppertDDlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:LiviVVlld:pubmed
pubmed-article:11592410pubmed:authorpubmed-author:Livi VMentaEElld:pubmed
pubmed-article:11592410pubmed:issnTypePrintlld:pubmed
pubmed-article:11592410pubmed:volume382lld:pubmed
pubmed-article:11592410pubmed:ownerNLMlld:pubmed
pubmed-article:11592410pubmed:authorsCompleteYlld:pubmed
pubmed-article:11592410pubmed:pagination1277-85lld:pubmed
pubmed-article:11592410pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:meshHeadingpubmed-meshheading:11592410...lld:pubmed
pubmed-article:11592410pubmed:year2001lld:pubmed
pubmed-article:11592410pubmed:articleTitlePyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors.lld:pubmed
pubmed-article:11592410pubmed:affiliationDiscovery Technologies, Preclinical Research Pharma, F.Hoffmann-LaRoche AG, Basel, Switzerland.lld:pubmed
pubmed-article:11592410pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11592410pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11592410lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11592410lld:pubmed